Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Identification of genomic alterations defining ovarian carcinoma subtypes may aid the stratification of patients to receive targeted therapies. We characterized high-grade serous ovarian carcinoma (HGSC) for the association of amplified and overexpressed genes with clinical outcome using gene expression data from 499 HGSC patients in the Ovarian Tumor Tissue Analysis cohort for 11 copy number amplified genes: ATP13A4, BMP8B, CACNA1C, CCNE1, DYRK1B, GAB2, PAK4, RAD21, TPX2, ZFP36, and URI. The Australian Ovarian Cancer Study and The Cancer Genome Atlas datasets were also used to assess the correlation between gene expression, patient survival, and tumor classification. In a multivariate analysis, high GAB2 expression was associated with improved overall and progression-free survival (P = 0.03 and 0.02), whereas high BMP8B and ATP13A4 were associated with improved progression-free survival (P = 0.004 and P = 0.02). GAB2 overexpression and copy number gain were enriched in the AOCS C4 subgroup. High GAB2 expression correlated with enhanced sensitivity in vitro to the dual PI3K/mTOR inhibitor PF-04691502 and could be used as a genomic marker for identifying patients who will respond to treatments inhibiting PI3K signaling. Mol Cancer Ther; 14(6); 1495–503. ©2015 AACR.

[1]  A. Tinker,et al.  "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? , 2014, Gynecologic oncology.

[2]  W. Hahn,et al.  In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene , 2014, Proceedings of the National Academy of Sciences.

[3]  D. Bowtell,et al.  Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.

[4]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[5]  Francesmary Modugno,et al.  Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[7]  K. Mimori,et al.  Gene expression of bone morphogenic protein 8B in the primary site, peripheral blood and bone marrow of patients with gastric cancer , 2013, Oncology letters.

[8]  Kylie L. Gorringe,et al.  Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer , 2013, Clinical Cancer Research.

[9]  E. Maizels,et al.  PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells , 2012, Proceedings of the National Academy of Sciences.

[10]  F. Villarroya,et al.  BMP8B Increases Brown Adipose Tissue Thermogenesis through Both Central and Peripheral Actions , 2012, Cell.

[11]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[12]  Yongping Wang,et al.  Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells , 2011, Oncogene.

[13]  A. Arcangeli,et al.  American Journal of Physiology-Cell Physiology theme: ion channels and transporters in cancer. , 2011, American journal of physiology. Cell physiology.

[14]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[15]  F. Davis,et al.  Ion channels and transporters in cancer. 4. Remodeling of Ca(2+) signaling in tumorigenesis: role of Ca(2+) transport. , 2011, American journal of physiology. Cell physiology.

[16]  H. Johnsen,et al.  Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.

[17]  Wilhelm Krek,et al.  URI is an oncogene amplified in ovarian cancer cells and is required for their survival. , 2011, Cancer cell.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[20]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[21]  Dorota A Crawford,et al.  The E646D-ATP13A4 Mutation Associated with Autism Reveals a Defect in Calcium Regulation , 2010, Cellular and Molecular Neurobiology.

[22]  S. Jeffrey,et al.  Focal amplification and oncogene dependency of GAB2 in breast cancer , 2010, Oncogene.

[23]  E Medico,et al.  The GAB 2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated to metastatic progression of breast cancer , 2022 .

[24]  Roger J Daly,et al.  Function, regulation and pathological roles of the Gab/DOS docking proteins , 2009, Cell Communication and Signaling.

[25]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[26]  D. Rimm,et al.  Gab2-mediated signaling promotes melanoma metastasis. , 2009, The American journal of pathology.

[27]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[28]  P. Harter,et al.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol) , 2009, Virchows Archiv.

[29]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[30]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[31]  C Blake Gilks,et al.  Amplification of 11q13 in ovarian carcinoma , 2008, Genes, chromosomes & cancer.

[32]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[33]  R. Paulson,et al.  A Novel Stat3 Binding Motif in Gab2 Mediates Transformation of Primary Hematopoietic Cells by the Stk/Ron Receptor Tyrosine Kinase in Response to Friend Virus Infection , 2007, Molecular and Cellular Biology.

[34]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[35]  F. Speleman,et al.  GAB2 is a novel target of 11q amplification in AML/MDS , 2006, Genes, chromosomes & cancer.

[36]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[37]  Roger J Daly,et al.  Increased Proliferation and Altered Growth Factor Dependence of Human Mammary Epithelial Cells Overexpressing the Gab2 Docking Protein* , 2006, Journal of Biological Chemistry.

[38]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[39]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[40]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[41]  X. Qi,et al.  Induction of primordial germ cells from murine epiblasts by synergistic action of BMP4 and BMP8B signaling pathways , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[43]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[44]  M. Braga,et al.  Exploratory Data Analysis , 2018, Encyclopedia of Social Network Analysis and Mining. 2nd Ed..

[45]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[46]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[47]  R. Pearson,et al.  Targeting PI3 kinase/AKT/mTOR signaling in cancer. , 2012, Critical reviews in oncogenesis.

[48]  Andrea Richardson,et al.  A role for the scaffolding adapter GAB2 in breast cancer , 2006, Nature Medicine.

[49]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.